Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib + bevacizumab first-line study in EGFR-mutant advanced NSCLC with malignant pleural and/or pericardial effusion
ChiCTR2100049102Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: 1-year progression-free survival rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
almonertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100049102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049102.